A Phase 2 interventional study of Romiplostim and Placebo in Idiopathic Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-10.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 19th largest by enrollment, is one of 2 that started in 2002, is one of 8 in phase 2, and was the 3rd registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2002; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 62 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen: 1 open now, 1 under way, 1 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2002, is one of 2 in phase 2, and was the 3rd registered.
Amgen’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2002.
2 of the studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 18 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with ITP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Two (including day -2) of the 3 counts taken during the screening and pre-treatment periods must have fulfilled the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Drug: Romiplostim
Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Drug: Romiplostim
Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
Drug: Romiplostim
Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Drug: Romiplostim
Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Drug: Romiplostim
Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
Drug: Romiplostim
Participants received placebo subcutaneously once a week for 6 weeks.
Drug: Placebo
Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
Drug: Romiplostim
Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
Drug: Romiplostim
Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.
Drug: Romiplostim
Administered by subcutaneous injection
Also known as: AMG 531, NPLATE
Administered by subcutaneous injection
Number of Participants With Adverse Events
Time frame: From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days
Number of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies
The development of antibodies to romiplostim or to endogenous thrombopoietin (eTPO) was assessed using a neutralizing bioassay. Participants positive for neutralizing antibodies at any of the assessments during the study are reported.
Time frame: Assessed on day 29 (Part A only), day 43 (Part B only), and day 78
Number of Participants Who Achieved Targeted Therapeutic Platelet Level in Part A
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and between 50 to 450 x 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part A
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Time frame: After first dose (day 1 to day 15 or 22), and after second dose (day 15 or 22 to day 78)
Number of Participants With a Peak Platelet Count ≥ 100 x 10⁹ Cells/L in Part A
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Number of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part A
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Peak Platelet Count After Each Dose in Part A
Platelet count data after the use of rescue medication were not included.
Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Change From Baseline in Peak Platelet Count After Each Dose in Part A
Platelet count data after the use of rescue medication were not included.
Time frame: Baseline and after first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Time to Peak Platelet Count After Each Dose in Part A
Platelet count data after the use of rescue medication were not included.
Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Duration Within the Targeted Therapeutic Platelet Range In Part A
Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and ≥ 50 and ≤ 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included.
Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 x 10⁹ cells/L and less than or equal to 450 x 10⁹ cells/L. Platelet count data after use of rescue medication were not included in the analysis.
Time frame: Day 1 to day 78
Percentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B
Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
Time frame: Day 1 to day 78
Percentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B
Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
Time frame: Day 1 to day 78
Percentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B
Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
Time frame: Day 1 to day 78
Percentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B
Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
Time frame: Day 1 to day 78
Peak Platelet Count in Part B
Platelet count data after administration of rescue medication were not included in the analysis.
Time frame: Day 1 to day 78
Change From Baseline in Peak Platelet Count in Part B
Platelet count data after administration of rescue medication were not included in the analysis.
Time frame: Baseline and day 1 to day 78
Time to Peak Platelet Count in Part B
Platelet count data after administration of rescue medication were not included in the analysis. Time to peak platelet count was analyzed using the Kaplan-Meier method.
Time frame: Day 1 to day 78
Duration Within the Targeted Therapeutic Platelet Range in Part B
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 × 10⁹ cells/L and less than or equal to 450 × 10⁹ cells/L. Platelet count data after administration of rescue medication were not included in the analysis.
Time frame: Day 1 to day 78
This study consisted of 2 parts. Part A (conducted from July 1, 2002 to October 13, 2003) was an open-label, dose-escalation trial with sequential cohorts of participants. Part B (conducted from October 6, 2003 to June 17, 2004) was a double-blind, placebo-controlled, parallel design study.
| Milestone | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 8 | 8 | 1 |
| Completed | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 8 | 8 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Participants | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 8 | 8 | 1 |
| Serious adverse events | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 |
| Treatment-related adverse events | 0 | 0 | 3 | 0 | 1 | 1 | 1 | 2 | 4 | 0 |
| Treatment-related serious adverse events | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Discontinuations due to adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The development of antibodies to romiplostim or to endogenous thrombopoietin (eTPO) was assessed using a neutralizing bioassay. Participants positive for neutralizing antibodies at any of the assessments during the study are reported.
| Participants | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-romiplostim neutralizing antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anti-eTPO neutralizing antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and between 50 to 450 x 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
| Participants | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg |
|---|---|---|---|---|---|---|
| After first dose | 1 | 0 | 0 | 1 | 1 | 1 |
| After second dose | 1 | 0 | 0 | 2 | 1 | 1 |
| After both doses | 1 | 0 | 0 | 1 | 1 | 1 |
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
| Participants | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg |
|---|---|---|---|---|---|---|
| After first dose | 1 | 1 | 1 | 2 | 2 | 3 |
| After second dose | 1 | 0 | 0 | 3 | 1 | 1 |
| After both doses | 1 | 0 | 0 | 2 | 1 | 1 |
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
| Participants | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg |
|---|---|---|---|---|---|---|
| After first dose | 1 | 0 | 0 | 1 | 2 | 3 |
| After second dose | 0 | 0 | 0 | 2 | 1 | 1 |
| After both doses | 0 | 0 | 0 | 1 | 1 | 1 |
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
| Participants | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg |
|---|---|---|---|---|---|---|
| After first dose | 0 | 0 | 0 | 0 | 1 | 2 |
| After second dose | 0 | 0 | 0 | 0 | 0 | 0 |
| After both doses | 0 | 0 | 0 | 0 | 0 | 0 |
Platelet count data after the use of rescue medication were not included.
| 1 × 10⁹ cells/L | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg |
|---|---|---|---|---|---|---|
| After first dose | 123.0 | — | — | 163.0 | 309.0 ± 202.2 | 746.3 ± 611.9 |
| After second dose | 65.0 | — | — | 140.5 ± 29.0 | 244.0 | 259.0 |
Platelet count data after the use of rescue medication were not included.
| 1 × 10⁹ cells/L | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg |
|---|---|---|---|---|---|---|
| After first dose | 109.5 | — | — | 150.2 | 289.3 ± 208.2 | 725.5 ± 622.5 |
| After second dose | 51.50 | — | — | 122.6 ± 21.78 | 220.0 | 231.7 |
Platelet count data after the use of rescue medication were not included.
| days | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg |
|---|---|---|---|---|---|---|
| After first dose | 10.0 (10 to 10) | — | — | 11.0 (11 to 11) | 9.5 (8 to 11) | 15.0 (12 to 15) |
| After second dose | 10.0 (10 to 10) | — | — | 11.0 (9 to 13) | 10.0 (10 to 10) | 11.0 (11 to 11) |
Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and ≥ 50 and ≤ 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included.
| days | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg |
|---|---|---|---|---|---|---|
| After first dose | 5.0 | — | — | 8.0 | 11.0 | 10.0 |
| After second dose | 3.0 | — | — | 3.5 ± 2.1 | 11.0 | 9.0 |
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 x 10⁹ cells/L and less than or equal to 450 x 10⁹ cells/L. Platelet count data after use of rescue medication were not included in the analysis.
| percentage of participants | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B | 25 | 88 | 38 | 0 |
Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
| percentage of participants | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Percentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B | 50 | 100 | 75 | 100 |
Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
| percentage of participants | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Percentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B | 25 | 63 | 63 | 100 |
Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
| percentage of participants | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Percentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B | 0 | 0 | 25 | 100 |
Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.
| percentage of participants | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Percentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B | 0 | 0 | 25 | 100 |
Platelet count data after administration of rescue medication were not included in the analysis.
| 1 × 10⁹ cells/L | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Peak Platelet Count in Part B | 80.8 ± 96.0 | 134.5 ± 90.2 | 240.9 ± 288.3 | 520.0 |
Platelet count data after administration of rescue medication were not included in the analysis.
| 1 × 10⁹ cells/L | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Change From Baseline in Peak Platelet Count in Part B | 52.4 ± 92.9 | 117.6 ± 88.3 | 226.9 ± 284.1 | 505.0 |
Platelet count data after administration of rescue medication were not included in the analysis. Time to peak platelet count was analyzed using the Kaplan-Meier method.
| days | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Time to Peak Platelet Count in Part B | 63 (27.5 to 78) | 18 (11.5 to 35.5) | 19 (11 to 35.5) | 21 (21 to 21) |
Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 × 10⁹ cells/L and less than or equal to 450 × 10⁹ cells/L. Platelet count data after administration of rescue medication were not included in the analysis.
| weeks | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|
| Duration Within the Targeted Therapeutic Platelet Range in Part B | 6.0 (6 to 6) | 3.0 (1 to 7) | 5.0 (1 to 7) | 4.0 (4 to 4) |
Collected over From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Romiplostim 0.2 µg/kg | — | 2/4 (50%) | 4/4 (100%) |
| Part A: Romiplostim 0.5 µg/kg | — | 0/4 (0%) | 4/4 (100%) |
| Part A: Romiplostim 1.0 µg/kg | — | 0/4 (0%) | 4/4 (100%) |
| Part A: Romiplostim 3 µg/kg | — | 0/4 (0%) | 4/4 (100%) |
| Part A: Romiplostim 6 µg/kg | — | 0/4 (0%) | 4/4 (100%) |
| Part A: Romiplostim 10 µg/kg | — | 1/4 (25%) | 4/4 (100%) |
| Part B: Placebo | — | 2/4 (50%) | 4/4 (100%) |
| Part B: Romiplostim 1.0 µg/kg | — | 0/8 (0%) | 8/8 (100%) |
| Part B: Romiplostim 3.0 µg/kg | — | 1/8 (12.5%) | 8/8 (100%) |
| Part B: Romiplostim 6.0 µg/kg | — | 0/1 (0%) | 1/1 (100%) |
| Event | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 | 0/8 | 1/8 | 0/1 |
| VertigoEar and labyrinth disorders | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/8 | 0/8 | 0/1 |
| Cerebral haemorrhageNervous system disorders | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/8 | 0/8 | 0/1 |
| Haemorrhage intracranialNervous system disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/8 | 0/8 | 0/1 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/8 | 0/8 | 0/1 |
| Deep vein thrombosisVascular disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/8 | 0/8 | 0/1 |
| Rectal haemorrhageGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/8 | 1/8 | 0/1 |
| ContusionInjury, poisoning and procedural complications | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/8 | 1/8 | 0/1 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/8 | 1/8 | 0/1 |
| Event | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/4 | 1/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/8 | 2/8 | 1/1 |
| Oral mucosal blisteringGastrointestinal disorders | 0/4 | 1/4 | 0/4 | 1/4 | 0/4 | 1/4 | 0/4 | 1/8 | 3/8 | 1/1 |
| Fungal infectionInfections and infestations | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/8 | 0/8 | 1/1 |
| HeadacheNervous system disorders | 1/4 | 2/4 | 3/4 | 4/4 | 1/4 | 0/4 | 0/4 | 2/8 | 3/8 | 0/1 |
| ContusionInjury, poisoning and procedural complications | 0/4 | 3/4 | 0/4 | 3/4 | 3/4 | 3/4 | 2/4 | 6/8 | 3/8 | 0/1 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/4 | 0/4 | 3/4 | 0/4 | 0/4 | 1/4 | 2/4 | 3/8 | 1/8 | 0/1 |
| Gingival bleedingGastrointestinal disorders | 0/4 | 1/4 | 0/4 | 1/4 | 1/4 | 0/4 | 1/4 | 0/8 | 4/8 | 0/1 |
| NauseaGastrointestinal disorders | 1/4 | 0/4 | 2/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/8 | 2/8 | 0/1 |
| Rectal haemorrhageGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 0/8 | 0/8 | 0/1 |
| StomatitisGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 | 2/4 | 1/8 | 1/8 | 0/1 |
| Age, Continuous(years) | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A | 43.5 ± 15.0 | 42.8 ± 11.1 | 42.5 ± 10.7 | 44.8 ± 18.2 | 41.3 ± 14.7 | 47.5 ± 14.5 | — | — | — | — | 43.7 ± 12.8 |
| Part B | — | — | — | — | — | — | 53.0 ± 10.6 | 43.0 ± 15.0 | 47.4 ± 16.6 | 42.0 ± NA | 14.3 ± 49.0 |
| Sex: Female, Male(Participants) | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 1 | 4 | 4 | 3 | 2 | 3 | 6 | 5 | 1 | 32 |
| Male | 1 | 3 | 0 | 0 | 1 | 2 | 1 | 2 | 3 | 0 | 13 |
| Race/Ethnicity, Customized(Participants) | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 5 | 1 | 36 |
| Black | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 3 |
| Hispanic | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 0 | 6 |
| Plateleet Count(1 × 10⁹ cells/L) | Part A: Romiplostim 0.2 µg/kg | Part A: Romiplostim 0.5 µg/kg | Part A: Romiplostim 1.0 µg/kg | Part A: Romiplostim 3 µg/kg | Part A: Romiplostim 6 µg/kg | Part A: Romiplostim 10 µg/kg | Part B: Placebo | Part B: Romiplostim 1.0 µg/kg | Part B: Romiplostim 3.0 µg/kg | Part B: Romiplostim 6.0 µg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A | 10.7 ± 2.70 | 14.5 ± 12.5 | 9.06 ± 4.19 | 13.4 ± 6.81 | 12.6 ± 9.00 | 18.4 ± 10.1 | — | — | — | — | 13.1 ± 7.93 |
| Part B | — | — | — | — | — | — | 28.4 ± 17.7 | 16.9 ± 7.86 | 14.0 ± 6.20 | 15.0 ± NA | 17.9 ± 10.6 |
No study locations are listed for this record.
Ran from Jul 2002 to primary completion in Jun 2004, 23 months.
Results were first posted in Jan 2020, 15 years 6 months after primary completion.
Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Purpura, Thrombocytopenic, Idiopathic →